A Master Services Agreement with AstraZeneca headlines Friday morning's small-cap news, with CelLBxHealth (AIM:CLBX) named as a qualified clinical-trial service provider to the pharma giant, a validation that arrives on the same day AstraZeneca itself secured a significant FDA approval. Elsewhere, Tooru (LSE:TOO.L) abandoned a planned acquisition, Clean Power Hydrogen (AIM:CPH2) disclosed serious equipment damage and a trading suspension, and Ocado (LSE:OCDO) struck a major new platform deal with Asda.
CelLBxHealth named AstraZeneca qualified service provider
CelLBxHealth (AIM:CLBX) has entered a Master Services Agreement with AstraZeneca under which it is designated a qualified service provider for the analysis of clinical trial samples. The agreement covers use of the company's Parsortix® circulating tumour cell platform, which isolates and harvests intact CTCs from patient blood samples for downstream analysis. The arrangement gives CelLBxHealth (AIM:CLBX) a direct commercial relationship with one of the world's largest pharmaceutical companies and positions the platform within active clinical development programmes.
Tooru abandons Mylky acquisition over debt and legal concerns
Tooru (AIM:TOO) has terminated its proposed acquisition of Mylky, concluding that completing the deal would have required the group to take on substantial new debt and accept exposure to unfamiliar European legal risk. The board determined that neither condition was acceptable given the company's current position and strategic priorities. The termination leaves Tooru without the transaction it had been pursuing and returns the company to evaluating its options independently.
Clean Power Hydrogen suspends trading after MFE220 unit sustains major damage
Clean Power Hydrogen (AIM:CPH2) disclosed that its MFE220 1MW membrane-free electrolyser unit sustained significant damage during the final Factory Acceptance Test at its Rossington facility. The incident has delayed completion of the unit and prompted a suspension of trading in the company's shares while the group assesses the financial implications and explores funding options. The MFE220 had been a centrepiece of the company's commercial pipeline, and the damage represents a material setback to its near-term delivery schedule.
Ocado to deploy Smart Platform across Asda's UK ecommerce estate
Ocado Group (LSE:OCDO) has agreed a commercial partnership with Asda to roll out the Ocado Smart Platform across Asda's UK online grocery business. Deployment is planned to begin from 2027, covering both stores and dark stores. The agreement represents one of the more significant domestic platform wins for Ocado in recent years, bringing a major UK supermarket chain onto its proprietary fulfilment and ecommerce technology at scale.
Europa Oil & Gas secures Equatorial Guinea approval for EG-08 farm-out
Europa Oil & Gas (AIM:EOG) announced that Antler, in which Europa holds a 42.9% stake, has received Ministry for Mining and Hydrocarbons Department approval for a farm-out of the EG-08 Production Sharing Contract to Fuhai. Under the terms of the transaction, Antler retains a 40% working interest and the operator role on the block. The ministerial sign-off clears the final regulatory hurdle for the deal and allows the partnership to advance work programme planning on EG-08.
Itaconix files patent and trademark for new plant-based paint range
Itaconix (AIM:ITX) has partnered with an established specialty paint company to develop and evaluate initial formulations for a new class of plant-based paint products. The company has filed both a patent application and a trademark application to protect the new product category. The collaboration marks Itaconix's entry into the decorative and functional coatings market as an application for its bio-derived polymer technology, extending beyond its existing personal care and home care segments.
Drax commissions first open-cycle gas turbine at Hirwaun
Drax Group (LSE:DRX) has successfully commissioned its first open-cycle gas turbine plant at Hirwaun in Wales and assumed commercial control of the asset. The Hirwaun OCGT adds flexible, fast-response generation capacity to Drax's portfolio and represents the first operational unit from the company's gas peaking development programme. Chief executive Will Gardiner described the commissioning as a landmark moment for the group as it builds out its flexible power generation capabilities alongside its existing biomass and hydro assets.
AstraZeneca wins FDA approval for Imfinzi in early bladder cancer
AstraZeneca (LSE:AZN) secured US Food and Drug Administration clearance for Imfinzi (durvalumab) in combination with BCG for adult patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer. The approval is supported by data from the POTOMAC Phase III trial, which demonstrated a 32% reduction in the risk of disease recurrence, progression or death. The indication covers an early-stage, high-risk patient population where treatment options have historically been, and the approval opens a new commercial opportunity for Imfinzi beyond its established lung and biliary tract cancer labels.
